射血分数保留心力衰竭患者药物治疗的进展  

The progress of drug treatment of heart failure with preserved ejection fraction

作　　者：郭衍楷 曹桂秋[1] 徐洁[1] 

机构地区：[1]新疆医科大学第五附属医院心内科,乌鲁木齐830011

出　　处：《疑难病杂志》2017年第9期951-954,958,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：新疆维吾尔自治区自然科学基金项目(2016D01C244)

摘　　要：近年来,随着诊疗技术的提高以及人口的老龄化,发现大量心力衰竭患者仍能保持相对正常的左室射血分数(LVEF),即射血分数保留心力衰竭(HF-PEF),且其逐渐成为心力衰竭发生的最常见形式。但目前HF-PEF治疗大多凭借的是临床经验,日渐增高的病死率迫切需要人们提出更好的治疗方案以提高其预后,故此文对HF-PEF的药物治疗作进一步综述。In recent years, with the improvement of medical technology and the aging of the population, it has found a large number of heart failure patients can still maintain a relatively normal left ventricular ejection fraction （LVEF）, which is preserved ejection fraction heart failure （HFPEF）, which has gradually become the most common form of heart failure, but the treatment is based on the most clinical experience, increased mortality rate in urgent need of people make better treatments to improve the prognosis, so we review the drug treatment for HFPEF.

关 键 词：射血分数保留的心力衰竭 药物治疗 

分 类 号：R541.6[医药卫生—心血管疾病]